Versuchen GOLD - Frei

Amagi IPO to test mkts with valuation reset

Mint Chennai

|

January 13, 2026

Nearly 90% of Amagi Media Labs' revenue comes from the US and Europe and no Indian peer operates at a comparable scale.

- Abhinaba Saha abhinaba.saha@livemint.com

Amagi Media Labs will open its ₹1,789 crore initial public offering (IPO) on 13 January, making it one of the first companies in 2026 to test public market appetite for a difficult-to-price global brand. The IPO comprises a ₹816 crore fresh issue and a ₹973 crore offer for sale.

Built in India and deployed worldwide, Amagi sells a cloud-based operating system that media companies use to run, distribute and monetize TV channels without owning broadcast infrastructure. Nearly 90% of its revenue comes from the US and Europe, the world’s largest advertising markets, and no Indian peer operates at a comparable scale.

Even globally, few companies span the full cloud value chain of media distribution the way Amagi does, according to its offer documents. While that positioning gives the company along growth runway, the lack of clear listed comparables leaves investors without an obvious benchmark.

Investors are being asked to judge Amagi largely on its earningstrajectory and how quickly this niche technology becomes mainstream, said Yatin Singh, chief executive officer (CEO) of investment banking at Emkay Global Financial Services. This uncertainty that is shaping the pricing of the IPO and expectations from the stock, said Singh.

WEITERE GESCHICHTEN VON Mint Chennai

Mint Chennai

Mint Chennai

Lenskart wants artificial intelligence to test your eyes

It expects AI-enabled eye testing to become the default foundational layer of eyecare delivery

time to read

3 mins

January 13, 2026

Mint Chennai

Mint Chennai

More companies to take a hit as labour codes debut

Reworked gratuity and leave encashments spell additional expenses for India Inc

time to read

2 mins

January 13, 2026

Mint Chennai

HC lifts ban on Zydus cancer biosimilar till patent expiry

In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.

time to read

2 mins

January 13, 2026

Mint Chennai

Trump’s investigation of Powell is also a warning to the next Fed chair

The criminal investigation into Federal Reserve Chair Jerome Powell isn’t ultimately about the Fed’s headquarters, or Powell, or even interest rates.

time to read

3 mins

January 13, 2026

Mint Chennai

Mint Chennai

States flag Almont-Kid syrup as tests find contaminants

Syrup found ‘Not of Standard Quality’ with contaminants like toxic ethylene glycol

time to read

1 mins

January 13, 2026

Mint Chennai

Mint Chennai

India at 100: Our choices today will define the next two decades

India's 2047 ambition is not guaranteed but achievable if we address all the potential pitfalls along our development path

time to read

4 mins

January 13, 2026

Mint Chennai

Now, inheritance works without probate—but why it still matters

Heirs can now act on a valid will without court cases, easing delays and unlocking assets in undisputed cases

time to read

6 mins

January 13, 2026

Mint Chennai

Why VCs have a new deep-tech playbook

where fundraising starts to drag,\" said Chand.

time to read

1 min

January 13, 2026

Mint Chennai

TCS, HCLTech deliver Q3 revenue surprise

clearer.

time to read

2 mins

January 13, 2026

Mint Chennai

Mint Chennai

US productivity is rising and it risks warping monetary policy

America's neutral rate ought to be going up but will the Fed listen?

time to read

3 mins

January 13, 2026

Listen

Translate

Share

-
+

Change font size